ReviewPLoS pathogens2026
Hippo signalling as a nexus in host-virus interactions.
Review in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hippo signalling pathway has emerged as an important regulator of host-virus interactions, linking antiviral immunity, viral replication, inflammation, and tissue remodelling. Recent studies show that upstream Hippo kinases such as MST1/2 and LATS1/2 often support antiviral responses, whereas YAP and TAZ can suppress innate immune signalling and may be exploited by viruses to promote infection. However, these effects are highly context dependent, varying according to viral species, cell type, infection stage, interferon signalling, inflammatory cues, and tissue damage. This short review summarises current evidence for Hippo-virus crosstalk and highlights how this pathway may shape both acute antiviral defence and longer-term pathological remodelling. We also discuss therapeutic opportunities and challenges, emphasising that targeting Hippo signalling requires caution because of its dual roles in antiviral immunity and tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.